2014年6月6日 · Stent thrombosis, MI, and Q-wave MI were all reduced with cangrelor compared with clopidogrel. The 48-hour outcomes were consistent across multiple subgroups and maintained at 30 days without degradation of the early effect.

This topic addresses the use of antiplatelet therapy in patients with acute ST-elevation myocardial infarction (STEMI) from presentation until discharge. Other relevant topics include: (See "Acute non-ST-elevation acute coronary syndromes: Initial antiplatelet therapy".)

2025年1月19日 · Clopidogrel is an antiplatelet medication approved for managing unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) in patients receiving fibrinolytic therapy.

2018年2月8日 · We examined whether P2Y 12 inhibitor choice changed among patients with recurrent MI, stent thrombosis, and/or unplanned revascularization during the first year after MI, and modeled factors associated with P2Y 12 inhibitor intensification (changing clopidogrel to prasugrel or ticagrelor).

2017年8月2日 · Clopidogrel reloading occurs most frequently in patients with acute myocardial infarction (MI) who are already taking clopidogrel, particularly for STEMI. Results from a recent study published in the European Heart Journal has now found that clopidogrol reloading does not cause an increased risk of in-hospital major bleeding or mortality.

2020年12月4日 · Aspirin is often combined with a P2Y12 receptor antagonist (clopidogrel, prasugrel, or ticagrelor) for dual antiplatelet therapy (DAPT) after PCI or ACS. 3,4 Aspirin monotherapy or DAPT may also be used to prevent major adverse cardiovascular events for patients with peripheral artery disease. 5 Oral anticoagulants, including warfarin and the di...

2013年11月1日 · Clopidogrel and ticagrelor are recommended for conservative medical management of MI in combination with aspirin (162 to 325 mg per day) for up to 12 months. Early administration of beta...

Clinical studies have shown that long-term DAPT with ASA and an antiplatelet such as clopidogrel, prasugrel or ticagrelor reduces the risk of death from CV causes, nonfatal MI or stroke after an acute ACS event 21–23. The first of the antiplatelets to demonstrate a …

2006年2月4日 · In patients with non-ST elevation ACS and those undergoing percutaneous coronary intervention (PCI), the combination of clopidogrel and aspirin reduces the risk of recurrent myocardial infarction (MI) or death by 20%–30% (Mehta et al 2001; Yusuf et al 2001; Steinhubl et al 2002).

The CURE 1 trial showed a significant improvement in the combined outcome of cardiovascular death, nonfatal MI, and stroke with the use of dual oral antiplatelet therapy (aspirin and clopidogrel). This benefit was seen as early as 24 hours after randomization and through to 12 months of follow-up.